U.S. Capital Markets Stock News

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...

Centrus Energy (LEU) opened Q1 2026 with revenue of US$76.7 million and basic EPS of US$0.51, against a backdrop of forecast earnings growth of about 7.0% a year and revenue growth around 5.1%. Over recent quarters the company has seen revenue range between US$73.1 million and US$154.5 million with basic EPS between US$0.21 and US$3.21. Trailing 12 month EPS sits at US$3.25 on revenue of US$452.3 million and net income of US$60.6 million, framing a set of results where profit growth and...

In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net loss of US$19.78 million, and raised its 2026 net sales guidance to a range of US$620 million to US$635 million. At the same time, Glaukos highlighted a broadened ophthalmic portfolio and long-term growth plan, even as insider share sales and continued losses underline ongoing execution and commercialization risks. We’ll now explore how...

Wondering if MKS at around US$293.77 is still offering value after a strong run, or if you might be turning up late to the story. The stock has posted returns of 10.7% over 7 days, 24.0% over 30 days, 74.5% year to date, 298.2% over 1 year and 255.7% over 3 years, with a 5 year return of 83.9%. These moves have kept MKS firmly on investors' radars, as sustained share price strength often raises questions about how the current price lines up with underlying fundamentals. With this context in...

In early May 2026, Autodesk launched “Autodesk for Small Business,” introducing a dedicated Small Business Hub, more flexible Autodesk Flex token purchasing, and May-only promotions including a free AutoCAD Professional Certification exam voucher for buyers. The initiative highlights Autodesk’s push to better serve small teams in Design and Make industries by simplifying product discovery, lowering upfront commitments, and incorporating small-business feedback directly into product...

What recent performance signals for Omeros (OMER) Without a single defining headline driving trading, Omeros (OMER) has still drawn attention after a strong month and past 3 months, alongside sizeable 1 year and 3 year total returns. At a recent price of $14.83 and a market cap of about $1.06b, the stock reflects a clinical stage pipeline built around immunologic and rare disease programs rather than current product revenue. See our latest analysis for Omeros. For context, Omeros has paired a...

To figure out whether MP Materials stock still offers value after its strong run, you need to separate a compelling story about rare earths from what the current share price already reflects. The stock last closed at US$72.65, with returns of 18.5% over 7 days, 42.0% over 30 days, 32.2% year to date, 207.6% over 1 year, 221.7% over 3 years and 192.9% over 5 years, so recent performance is front of mind for many investors. Recent news around rare earth supply chains and US focused production...

Wondering if Nextpower at US$126.08 is still offering value after its strong run, or if you might be late to the story. The stock shows returns of 10.3% over 7 days, 16.7% over 30 days, 35.9% year to date and 188.1% over 1 year, with a 3 year return of 279.4%. This naturally raises questions about what is already priced in. Recent coverage has focused on how quickly Nextpower's share price has moved relative to its sector peers and on the growing investor interest in companies linked to...

Wondering whether Academy Sports and Outdoors at around US$54.46 is still priced attractively, or if most of the easy upside is gone? This article focuses squarely on what the numbers say about value. The stock has returned 4.4% year to date and 36.7% over the past year, while the past 30 days and 7 days show declines of 4.8% and 0.7%. This can change how the market is thinking about risk and opportunity. Recent coverage around Academy Sports and Outdoors has centered on how the business is...

If you are wondering whether TTM Technologies at around US$164.64 still offers value after a strong run, or if you are late to the story, this article breaks down what that price represents. The stock has posted very strong returns, including 19.7% over the last 7 days, 72.0% over 30 days, 133.2% year to date and a very large gain over the last year and multi year periods, which can change how the market is pricing both upside and risk. Recent coverage has focused on TTM Technologies because...

JetBlue Airways (NasdaqGS:JBLU) has rolled out new premium benefits on its JetBlue Premier World Elite Mastercard, including companion passes, higher travel rewards, expanded statement credits, and fitness-related perks. The airline is also offering a limited-time loyalty status match to its TrueBlue Mosaic program aimed at stranded Spirit Airlines customers. These moves are being introduced alongside JetBlue's aggressive expansion in Fort Lauderdale as Spirit exits the market. For...

What is driving sentiment around Telephone and Data Systems stock? Telephone and Data Systems (TDS) is under pressure after an earnings update coincided with heavy fiber investment, uncertainty following the wireless business sale, insider selling reports, a class action deadline, and technical downgrades. See our latest analysis for Telephone and Data Systems. The recent earnings disappointment and concerns around fiber spending, insider activity, and legal overhang come after a 10.89% year...

Some investors may be wondering if Napco Security Technologies at around US$41 is still offering value after its strong run, or if most of the opportunity is already priced in. The stock has seen mixed short term moves, with an 8.7% decline over the last week and a 2.5% gain over the last month. The 1 year return sits at 67.9% and the 5 year return at 165.9%. Recent coverage has focused on Napco Security Technologies as investors reassess growth expectations and risk after these share price...

Investors may be wondering if TKO Group Holdings at around US$190 a share is still priced attractively, or if most of the easy upside has already been captured. The stock closed at US$190.47, with a 3.7% gain over the last 7 days, a 3.3% decline over 30 days, an 8.0% decline year to date, and a 13.8% return over the last year, so the recent moves give a mixed picture of momentum and risk. Those swings sit against a longer track record where 3 year returns are 91.6% and 5 year returns are...

ITT (ITT) opened 2026 with Q1 revenue of US$1.2 billion and basic EPS of US$0.89, setting the tone for how the year could unfold against its recent track record. The company has seen quarterly revenue move from US$913 million in Q1 2025 to US$1.2 billion in Q1 2026, while basic EPS ranged from US$1.33 in Q1 2025 to US$1.65 in Q4 2025 before the latest Q1 print. This puts the focus firmly on how much of this top line is flowing through to margins. See our full analysis for ITT. With the latest...

If you are wondering whether Zoetis at around US$111 is a bargain or a value trap, this article will explain what the current price might be implying about the stock. The stock has recently retreated, with returns of 2.3% over 7 days, 6.0% over 30 days, 11.7% year to date, and 27.6% over 1 year. This may have shifted how the market views its risk and reward trade off. Recent coverage has focused on Zoetis as a major animal health company, highlighting how the sector can be influenced by...

Hasbro has signed a long term lease for new creative office space at The Lot at Formosa in West Hollywood. The move expands Hasbro's presence at a historic Hollywood studio campus in the core of the entertainment production district. The new space is intended to support the company’s growing focus on branded entertainment and content related activities. For investors watching NasdaqGS:HAS, the new lease lands at a time when the stock trades at $97.48, with returns of 3.7% over the past...

Revolution Medicines (NasdaqGS:RVMD) sent a cease and desist letter to Erasca, alleging patent infringement and trade secret misappropriation around RAS inhibitor programs. The company advanced daraxonrasib’s regulatory path and released new Phase 3 data, ahead of a high profile ASCO Plenary Presentation. The combination of legal action and clinical progress raises fresh questions about future market exclusivity, licensing potential, and competitive positioning in RAS targeted...

Coupang (CPNG) opened Q1 2026 with revenue of about US$8.5b and a basic EPS loss of US$0.15, alongside a trailing twelve month basic EPS loss of US$0.09 on revenue of roughly US$35.1b. This keeps the focus firmly on how efficiently that scale is translating into earnings. Over recent quarters the company has seen revenue move from about US$7.9b in Q1 2025 to US$9.3b in Q3 2025 before landing at US$8.5b this quarter. Over the same period, quarterly basic EPS has swung from a profit of US$0.06...

Core Scientific (NasdaqGS:CORZ) has agreed to acquire Polaris DS LLC as part of a plan to expand its Muskogee, Oklahoma data center campus. The Muskogee project is aimed at adding power capacity focused on high-density colocation and AI oriented workloads. This move reflects a greater focus on AI and high-performance computing infrastructure alongside Core Scientific's existing Bitcoin mining operations. Core Scientific, trading at $24.63, has delivered a 25.9% return over the past week and...

Aurinia Pharmaceuticals Inc. has reported its first-quarter 2026 results, with revenue rising to US$77.71 million and net income to US$34.36 million, lifting diluted earnings per share from continuing operations to US$0.25 compared with US$0.16 a year earlier. The quarter underscored the growing commercial role of LUPKYNIS in lupus nephritis, as higher sales and improved gross margins helped Aurinia deliver stronger profitability while reaffirming its 2026 revenue guidance. Next, we’ll...